+

WO2008035001A3 - Composition destinee au traitement de la sclerose laterale amyotrophique - Google Patents

Composition destinee au traitement de la sclerose laterale amyotrophique Download PDF

Info

Publication number
WO2008035001A3
WO2008035001A3 PCT/FR2007/051947 FR2007051947W WO2008035001A3 WO 2008035001 A3 WO2008035001 A3 WO 2008035001A3 FR 2007051947 W FR2007051947 W FR 2007051947W WO 2008035001 A3 WO2008035001 A3 WO 2008035001A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
lateral sclerosis
amyotrophic lateral
treatment
conjugate
Prior art date
Application number
PCT/FR2007/051947
Other languages
English (en)
Other versions
WO2008035001A2 (fr
Inventor
Michel Geffard
Original Assignee
Gemac
Michel Geffard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemac, Michel Geffard filed Critical Gemac
Priority to JP2009527873A priority Critical patent/JP2010503645A/ja
Priority to EP07823842A priority patent/EP2063880A2/fr
Priority to US12/441,808 priority patent/US20090318384A1/en
Priority to CA002663272A priority patent/CA2663272A1/fr
Publication of WO2008035001A2 publication Critical patent/WO2008035001A2/fr
Publication of WO2008035001A3 publication Critical patent/WO2008035001A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'objet de l'invention est l'utilisation d'une composition pour maîtriser l'évolution de la Sclérose Latérale Amyotrophique, caractérisée en ce qu'elle comprend au moins : un conjugué entre la Poly-Lysine et au moins un anti-oxydant, et un conjugué entre la Poly-Lysine et au moins un acide gras. L'invention concerne également une composition particulière pour maîtriser l'évolution de la Sclérose Latérale Amyotrophique.
PCT/FR2007/051947 2006-09-18 2007-09-17 Composition destinee au traitement de la sclerose laterale amyotrophique WO2008035001A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009527873A JP2010503645A (ja) 2006-09-18 2007-09-17 筋萎縮性側索硬化症の治療のための合剤
EP07823842A EP2063880A2 (fr) 2006-09-18 2007-09-17 Composition destinee au traitement de la sclerose laterale amyotrophique
US12/441,808 US20090318384A1 (en) 2006-09-18 2007-09-17 Composition intended for the treatment of amyotrophic lateral sclerosis
CA002663272A CA2663272A1 (fr) 2006-09-18 2007-09-17 Composition destinee au traitement de la sclerose laterale amyotrophique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0653789 2006-09-18
FR0653789A FR2905868B1 (fr) 2006-09-18 2006-09-18 Composition destinee au traitement de la sclerose laterale amyotrophique

Publications (2)

Publication Number Publication Date
WO2008035001A2 WO2008035001A2 (fr) 2008-03-27
WO2008035001A3 true WO2008035001A3 (fr) 2008-05-22

Family

ID=37907089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/051947 WO2008035001A2 (fr) 2006-09-18 2007-09-17 Composition destinee au traitement de la sclerose laterale amyotrophique

Country Status (6)

Country Link
US (1) US20090318384A1 (fr)
EP (1) EP2063880A2 (fr)
JP (1) JP2010503645A (fr)
CA (1) CA2663272A1 (fr)
FR (1) FR2905868B1 (fr)
WO (1) WO2008035001A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072513A1 (fr) 2015-03-26 2016-09-28 Medday Biotin pour le traitement de la sclérose latérale amyotrophique
FR3048616B1 (fr) * 2016-03-14 2018-04-06 Polyneuros Polycomplexes de composes poly-lysine pour la prevention et/ou la lutte contre la sclerose laterale amyotrophique
FR3066393B1 (fr) 2017-05-16 2019-07-19 Polyneuros Principe actif constitue par un melange de composes poly-lysine et utilisation dans la prevention des avc et le traitement de la phase inflammatoire post-avc
FR3122573B1 (fr) * 2021-05-10 2024-03-29 Hydro Fill Tech Compositions de conjugués poly-lysine et de micelles et/ou de copolymères de poly-lysine
FR3122571B1 (fr) * 2021-05-10 2023-05-12 Hydro Fill Tech Compositions et leur utilisation pour rétablir la perméabilité intestinale et/ou prévenir ou lutter contre des maladies multifactorielles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
WO2006125930A1 (fr) * 2005-05-27 2006-11-30 Gemac Composition destinee au traitement de la sclerose en plaques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788962A (en) * 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
WO1996015810A1 (fr) * 1994-11-18 1996-05-30 Michel Geffard Conjugues monofonctionnels et/ou polyfonctionnels de la polylysine
WO2006125930A1 (fr) * 2005-05-27 2006-11-30 Gemac Composition destinee au traitement de la sclerose en plaques
FR2886153A1 (fr) * 2005-05-27 2006-12-01 Gemac Sa Composition destinee au traitement de la sclerose en plaques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JACKSON M ET AL: "THERAPEUTIC DEVELOPMENTS IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 11, no. 10, 1 October 2002 (2002-10-01), pages 1343 - 1364, XP008035103, ISSN: 1354-3784 *

Also Published As

Publication number Publication date
CA2663272A1 (fr) 2008-03-27
FR2905868A1 (fr) 2008-03-21
EP2063880A2 (fr) 2009-06-03
US20090318384A1 (en) 2009-12-24
FR2905868B1 (fr) 2012-12-21
JP2010503645A (ja) 2010-02-04
WO2008035001A2 (fr) 2008-03-27

Similar Documents

Publication Publication Date Title
WO2007146965A3 (fr) Composés destinés au traitement d'une maladie périodontale
WO2007095316A3 (fr) Compositions et procédés pour formulations à base d'oligonucléotides
EP1987141B8 (fr) Compositions de traitement des maladies médiées par le collagène
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
WO2006093348A3 (fr) Procede et composition destines au traitement des maladies vasculaires peripheriques
IL223477A (en) Pharmaceutical preparation containing modified enzyme uricase
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
WO2008115469A3 (fr) Rôle de la signalisation par hérisson dans l'athérosclérose et les maladies cardiovasculaires
WO2008084495A3 (fr) Nouvelle composition agricole
WO2008070129A3 (fr) Compositions et procédés pour le traitement de maladie inflammatoire
WO2007084857A3 (fr) Procédés et compositions de traitement de troubles prolifératifs cellulaires
WO2008061724A3 (fr) Compositions innovantes
WO2007138466A3 (fr) Compositions pharmaceutiques comprenant une combinaison de meloxicam et de tramadol
WO2006105538A3 (fr) Methodes et compositions de traitement de pathologies afferentes a l'il-21
WO2005091853A3 (fr) Procedes et compositions pour traiter des pathologies associees a l'il-13
WO2009141541A3 (fr) Utilisation d' inhibiteurs de kif13a et d ' ap-1 pour inhiber la melanogenese
WO2007100561A3 (fr) Utilisation de dha et d'ara pour la preparation d'une composition destinee a la prevention ou au traitement de l'obesite
WO2010072787A3 (fr) Composition et méthode de traitement d'états pathologiques cutanés
WO2010012386A3 (fr) Méthode de traitement de dents hypersensibles
WO2007144057A3 (fr) Carbone antimicrobien
WO2008035001A3 (fr) Composition destinee au traitement de la sclerose laterale amyotrophique
WO2010062506A3 (fr) Inhibiteurs de cyp17 décahydro-1h-indénoquinolinone et décahydro-3h-cyclopentaphénanthridinone
WO2008019782A3 (fr) Dispersions d'agents contenant des nanoparticules d'urée
WO2007125521A3 (fr) Formes polymorphiques de l'acide zolédronique et leurs procédés de synthèse
WO2008070602A3 (fr) Composition pharmaceutique topique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07823842

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2009527873

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2663272

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007823842

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12441808

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载